Author(s): Zhang X, Sun J
Abstract Share this page
Abstract OBJECTIVE: To explore the safety and efficacy of lower dose of rituximab in the treatment of elderly autoimmune hemolytic anemia (AIHA). METHODS: From May 2008 to February 2013, a total of 37 patients with newly diagnosed elderly AIHA patients were enrolled in the study, including 25 cases treated with prednisone 1 mg · kg⁻¹ · d⁻¹ for 4 weeks and 12 cases ineligible for glucocorticoid receiving rituximab (100 mg/week for 4 times). RESULTS: Of the 25 patients with conventional glucocorticoid, 5 cases (20.0\%) were complete remission (CR), 15 cases with partial remission (PR) and 5 cases without response. The overall response rate was 80.0\%. Of the 12 cases with rituximab, 8 cases (66.7\%) were CR, 3 cases with PR and 1 without response. The overall response rate was 91.7\%. A significantly higher CR rate was seen in lower dose of rituximab, as compared to that in conventional glucocorticoid (P=0.038). CONCLUSION: A lower dose of rituximab, with satisfactory safety and efficacy, was better than the conventional glucocorticoid in the treatment of elderly AIHA patients.
This article was published in Zhonghua Xue Ye Xue Za Zhi
and referenced in General Medicine: Open Access